Tagged with IMI

Pharma Antimicrobial resistance is classified by the WHO as one of the top threats to humanity. The Business Unit Director for Europe and America of DSM Sinochem Pharmaceuticals, a global leader in environmentally friendly anti-infective molecules, explains the risks related to antimicrobial resistance, the role of the pharmaceutical industry and how…

pharma The managing director of Adcock Ingram’s prescription business, Ashley Pearce highlights the division’s strategic placement within the group’s overall activities, and how he plans on leveraging partnerships with various multinationals, expand into biosimilars and grow the generics business into a market leading position. Adcock Ingram has undergone several strategic changes…

pharma  Pfizer Global Established Products’ BU Head and  Hospira’s Director of Institutional Affairs tell us about Pfizer’s recent major acquisition of Hospira, their post-merger strategy for increasing market access, as well as the challenges faced by the French biosimilars market and what Pfizer-Hospira is doing to achieve the huge potential in…

Pharma The general manager of Drogsan, Ersan Kuçuk elaborates on the company’s efforts in shifting towards more value-added pharmaceutical products, specifically within the realm of biosimilars, while highlighting his ambitions in expanding the company’s presence within OTC. He also illustrates the decision to move Drogsan’s R&D department to the Gazi University…

pharma Haluk Ataoglu, academic turned founder of Matriks Biotek®, talks about his aspirations for his company and the Turkish R&D landscape as well as how to penetrate the global pharmaceutical market as a Turkish brand. As an introduction Haluk, can you tell us what your initial aspirations were in starting Matriks…

life sciences John Taboas is the president of Biopharma Consulting Services (BCS), a leader in visual inspection and other validation and engineering services. Here he tells PharmaBoardroom how the company is working to position Puerto Rico as a hub for subject matter experts in visual inspection, with a new training facility and inspection…

biosimilars Akhilesh Vijay came to Accord Healthcare Peru following a career at Intas Pharmaceutical in India. He urges the implementation of regulation for Biosimilars and discusses his strategy for future growth as a leading Indian generic affiliate. How did you integrate yourself here, and what was the initial strategy? What is…

biosimilars Christopher Ko was appointed as the Chief Executive Officer of Samsung Bioepis in 2012, then newly founded Korean pharmaceutical company with expertise in biosimilars. In this interview, he discusses the opportunities in Biosimilar markets as well as the potential impact the Samsung brand will bring to the pharmaceutical industry. As…

biosimilars Brothers Juan José and Andrés Aguirre Salazar of Grupo Bruluart talk about the company’s most important milestones and how they are institutionalizing the family business to prepare the firm for new market opportunities. Could you walk us through the most important milestones of the company and provide our readers with…

investemnt The stability of Peru’s economy in recent years has provided amply opportunity for multinational pharmaceutical companies to invest in the country. Augusto Rey de la Cuba, executive director of ALAFARPE (Asociación Nacional de Laboratorios Faramcéuticos de Perú), discusses intellectual property issues and investing in research in the country. Can you…

biosimilar Laboratorios Elea’s General Manager tells the story of the laboratories outstanding growth over the previous five years, the his firms upcoming launch of the first Argentinian developed biosimilar product. To begin, would you please introduce yourself and Elea to our readers? I joined Elea four years ago as general manager,…

similars The vice president of Laboratorios Beta discusses the factors of why his organization is on the  way to consolidating its different business lines and becoming a pure pharmaceutical company.     2014 marks the 74th anniversary of Laboratorios Beta. To what extent is the company today still the same company…